Plain-English translation of NCT05362773 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This is one of the first times this treatment has been tested in people.
This is a Phase 1 trial of , a new type of medication designed to direct your immune cells to find and destroy cancer cells in certain blood cancers. The study is testing whether this medication is safe and effective for patients whose cancer has not responded to standard treatments or has come back after treatment. Researchers will monitor you carefully to understand how your body handles the medication and how well it works.
Patients with certain blood cancers often run out of standard treatment options when their cancer stops responding or comes back. This medication represents a new approach by using your own immune system to target cancer cells, offering hope for patients who have limited choices.
You would receive the medication through injections in consecutive 28-day cycles for up to 12 months, unless your cancer progresses or side effects become intolerable. Throughout the trial, you would have regular visits for blood tests, scans to measure your cancer response (checked after the first cycle and then every other cycle), and check-ups to monitor for side effects. The study team will closely track how you respond and adjust your dose based on safety information from other participants.
AI-generated summary from trial data · Jun 6, 2026 · Not medical advice
United States